Matthys Imke, Defreyne Justine, Elaut Els, Fisher Alessandra Daphne, Kreukels Baudewijntje P C, Staphorsius Annemieke, Den Heijer Martin, T'Sjoen Guy
Department of Endocrinology, Ghent University Hospital, 9000 Ghent, Belgium.
Center for Sexology and Gender, Ghent University Hospital, 9000 Ghent, Belgium.
J Clin Med. 2021 Jan 14;10(2):296. doi: 10.3390/jcm10020296.
Improving transgender people's quality of life (QoL) is the most important goal of gender-affirming care. Prospective changes in affect can influence QoL. We aim to assess the impact of initiating gender-affirming hormonal treatment (HT) on affect. In the European Network for the Investigation of Gender Incongruence (ENIGI) study, we prospectively collected data of 873 participants (451 transwomen (TW) and 422 transmen (TM)). At baseline, psychological questionnaires including the Positive and Negative Affect Schedule (PANAS) were administered. The PANAS, levels of sex steroids and physical changes were registered at each follow-up visit during a 3-year follow-up period, starting at the initiation of hormonal therapy. Data were analyzed cross-sectionally and prospectively. Over the first three months, we observed a decline in positive affect (PA) in both TM and TW. Thereafter, PA reached a steady state in TW, whereas in TM there was also a second decline at 18 months. In both TM and TW there was no persisting difference comparing baseline to the 36-months results. Concerning negative affect (NA), we observed a decline during the first year in TM, which sustained during the second year and was not different anymore at 36 months compared to baseline. In TW though, we did not find any change of NA during the entire follow-up. Even if some of these results show significant differences, they should be considered with caution, since there was no control group and the absolute differences are small. No association between affect and the level of sex steroids was observed. Baseline QoL and psychological burden are related to affect independently from gender but are not necessarily good predictors of the evolution of one's affect during the gender-affirming process. Further research is necessary to investigate these preliminary results.
改善跨性别者的生活质量是性别肯定治疗的最重要目标。情感方面的预期变化会影响生活质量。我们旨在评估开始性别肯定激素治疗(HT)对情感的影响。在欧洲性别认同不一致调查网络(ENIGI)研究中,我们前瞻性地收集了873名参与者(451名跨性别女性(TW)和422名跨性别男性(TM))的数据。在基线时,进行了包括积极和消极情感量表(PANAS)在内的心理问卷调查。从激素治疗开始起,在3年的随访期内,每次随访时记录PANAS、性类固醇水平和身体变化。对数据进行了横断面分析和前瞻性分析。在最初的三个月里,我们观察到TM和TW的积极情感(PA)均有所下降。此后,TW的PA达到稳定状态,而TM在18个月时也出现了第二次下降。在TM和TW中,将基线与36个月的结果进行比较时,均未发现持续差异。关于消极情感(NA),我们观察到TM在第一年有所下降,在第二年持续下降,与基线相比,36个月时不再有差异。然而,在TW中,我们在整个随访期间未发现NA有任何变化。即使其中一些结果显示出显著差异,但由于没有对照组且绝对差异较小,因此应谨慎考虑。未观察到情感与性类固醇水平之间的关联。基线生活质量和心理负担与情感相关,与性别无关,但不一定是性别肯定过程中个人情感演变的良好预测指标。需要进一步研究来调查这些初步结果。